[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453989":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":36,"overallOfficials":11,"centralContacts":46,"locations":52,"responsibleParty":137,"collaborators":11,"id":139,"slug":11,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":11,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":11,"maxAge":146,"enrollmentInfo":147,"targetDuration":11,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"EyePoint Pharmaceuticals, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Grade of anterior chamber cells (ACC)",null,"Post-Operative Day 14",[14],{"measure":15,"description":11,"timeFrame":12},"Grade of anterior chamber flare (ACF)",{"allocation":17,"interventionModel":18,"interventionModelDescription":19,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"RANDOMIZED","PARALLEL","Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"DEXYCU (dexamethasoneintraocular suspension) 9%","EXPERIMENTAL","A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.",[29],"Drug: Dexamethasone",{"label":31,"type":32,"description":33,"interventionNames":34},"Prednisolone acetate ophthalmic suspension (USP) 1%","ACTIVE_COMPARATOR","Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.",[35],"Drug: Prednisolone Acetate Ophthalmic",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","Dexamethasone","single anterior chamber injection",[25],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"Prednisolone Acetate Ophthalmic","topical administration four times a day for 28 days, followed by treatment taper",[31],[47],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Ramiro Ribeiro, MD, PhD","CONTACT","833-393-7646","rribeiro@eyepointpharma.com",[53,67,76,86,95,104,113,120,128],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":11},"EyePoint Investigational Site","RECRUITING","Huntington Beach","California","92647","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-117.99923,33.6603,{"lat":65,"lon":64},{"facility":54,"status":68,"city":69,"state":57,"zip":70,"country":59,"countryCode":60,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"ACTIVE_NOT_RECRUITING","Palo Alto","94303",{"type":62,"coordinates":72},[73,74],-122.14302,37.44188,{"lat":74,"lon":73},{"facility":77,"status":55,"city":78,"state":79,"zip":80,"country":59,"countryCode":60,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"EyePoint Investigative Site","Boston","Massachusetts","02118",{"type":62,"coordinates":82},[83,84],-71.05977,42.35843,{"lat":84,"lon":83},{"facility":54,"status":55,"city":87,"state":88,"zip":89,"country":59,"countryCode":60,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"Jackson","Mississippi","39216",{"type":62,"coordinates":91},[92,93],-90.18481,32.29876,{"lat":93,"lon":92},{"facility":54,"status":55,"city":96,"state":97,"zip":98,"country":59,"countryCode":60,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"Omaha","Nebraska","68114",{"type":62,"coordinates":100},[101,102],-95.94043,41.25626,{"lat":102,"lon":101},{"facility":54,"status":55,"city":105,"state":106,"zip":107,"country":59,"countryCode":60,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"Buffalo","New York","14209",{"type":62,"coordinates":109},[110,111],-78.87837,42.88645,{"lat":111,"lon":110},{"facility":77,"status":55,"city":106,"state":106,"zip":114,"country":59,"countryCode":60,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"10032",{"type":62,"coordinates":116},[117,118],-74.00597,40.71427,{"lat":118,"lon":117},{"facility":54,"status":55,"city":121,"state":106,"zip":122,"country":59,"countryCode":60,"cosmosGeoPoint":123,"geoPoint":127,"contacts":11},"Rochester","14642",{"type":62,"coordinates":124},[125,126],-77.61556,43.15478,{"lat":126,"lon":125},{"facility":54,"status":55,"city":129,"state":130,"zip":131,"country":59,"countryCode":60,"cosmosGeoPoint":132,"geoPoint":136,"contacts":11},"Charleston","South Carolina","29425",{"type":62,"coordinates":133},[134,135],-79.93275,32.77632,{"lat":135,"lon":134},{"type":138,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100453989",false,"NCT05191706","Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","Inclusion Criteria:\n\n* Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation.\n* If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content).\n* Other protocol-specified inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the investigator.\n* Has a post-traumatic cataract.\n* Presence of active or suspected viral, bacterial, or fungal disease in the study eye.\n* Ocular hypertension with an IOP in the study eye \\>25 mmHg at Screening with or without treatment with anti-glaucoma monotherapy.\n* Subjects who have received a periocular corticosteroid injection in the study eye in the 3 months prior to Screening.\n* Subjects who have received any intravitreal corticosteroid delivery vehicle (eg, Retisert®, Ozurdex®, Iluvien®) in the study eye at any time.\n* Other protocol-specified exclusion criteria may apply","ALL","3 Years",{"count":148,"type":149},60,"ESTIMATED","INTERVENTIONAL",[152],"PHASE4","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",[155],"Cataract",[157,158],"pediatric","cataract","2025-04-01",{"date":161,"type":162},"2025-04-03","ACTUAL",{"date":164,"type":162},"2022-01-04",{"date":166,"type":149},"2026-02",{"name":5,"class":6},9]